Compare MasTec Inc (MTZ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Zimmer Biomet Holdings Inc — how do they compare? MasTec Inc trades at $348.86 (market cap $26.60B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: MasTec Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | ZBH | |
|---|---|---|
Market Cap | $26.60B | $17.36B |
Sector | Technology | Health |
52-Week High | $437.51 | $107.71 |
52-Week Low | $172.51 | $79.58 |
Enterprise Value | $29.34B | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MasTec (MTZ) trades at $336.61, up 2.13% today, amid strong analyst sentiment with 32 of 36 analysts rating it a Buy. The stock shows robust fundamentals with Q1 2026 EPS beating estimates by 40.6% and a record $20.3 billion backlog. Recent $1.65 billion acquisition of The Superior Group enhances data center infrastructure capabilities, positioning MTZ for AI-driven power demand growth. Technical indicators are bearish overall, with the stock trading near pivot point resistance at $338.
Outlook remains positive given earnings momentum and strategic expansion, though high P/E of 58.95 poses valuation risk. Upside to consensus price target of $497.45 offers 47.8% potential, but investors face execution risks from integration and debt-funded acquisitions. Revenue growth to $15.3 billion in 2026 supports bullish thesis if margins hold.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
